Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 6
2008 2
2009 3
2010 2
2011 4
2012 2
2013 4
2014 2
2015 4
2016 4
2017 3
2018 4
2019 7
2020 5
2021 6
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Therapy-induced normal tissue damage promotes breast cancer metastasis.
Perkins DW, Steiner I, Haider S, Robertson D, Buus R, O'Leary L, Isacke CM. Perkins DW, et al. Among authors: buus r. iScience. 2023 Nov 22;27(1):108503. doi: 10.1016/j.isci.2023.108503. eCollection 2024 Jan 19. iScience. 2023. PMID: 38161426 Free PMC article.
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
Gazinska P, Milton C, Iacovacci J, Ward J, Buus R, Alaguthurai T, Graham R, Akarca A, Lips E, Naidoo K, Wesseling J, Marafioti T, Cheang M, Gillett C, Wu Y, Khan A, Melcher A, Salgado R, Dowsett M, Tutt A, Roxanis I, Haider S, Irshad S. Gazinska P, et al. Among authors: buus r. Clin Cancer Res. 2022 Oct 14;28(20):4494-4508. doi: 10.1158/1078-0432.CCR-22-0543. Clin Cancer Res. 2022. PMID: 36161312 Free PMC article.
Genetic epidemiologic studies of preterm birth: guidelines for research.
Pennell CE, Jacobsson B, Williams SM, Buus RM, Muglia LJ, Dolan SM, Morken NH, Ozcelik H, Lye SJ; PREBIC Genetics Working Group; Relton C. Pennell CE, et al. Among authors: buus rm. Am J Obstet Gynecol. 2007 Feb;196(2):107-18. doi: 10.1016/j.ajog.2006.03.109. Am J Obstet Gynecol. 2007. PMID: 17306646 Review.
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
Melake MJ, Smith HG, Mansfield D, Davies E, Dillon MT, Wilkins AC, Patin EC, Pedersen M, Buus R, Melcher AA, Thway K, Miah AB, Zaidi SH, Hayes AJ, Fenton TR, Harrington KJ, McLaughlin M. Melake MJ, et al. Among authors: buus r. Oncoimmunology. 2022 May 9;11(1):2066050. doi: 10.1080/2162402X.2022.2066050. eCollection 2022. Oncoimmunology. 2022. PMID: 35558159 Free PMC article.
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Pece S, Sestak I, Montani F, Tillhon M, Maisonneuve P, Freddi S, Chu K, Colleoni M, Veronesi P, Disalvatore D, Viale G, Buus R, Cuzick J, Dowsett M, Di Fiore PP. Pece S, et al. Among authors: buus r. Eur J Cancer. 2022 Mar;164:52-61. doi: 10.1016/j.ejca.2022.01.003. Epub 2022 Feb 15. Eur J Cancer. 2022. PMID: 35172273 Free article. Clinical Trial.
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck B, Bland P, Mavrommati I, Muirhead G, Cottom H, Wai PT, Maguire SL, Barker HE, Morrison E, Kriplani D, Yu L, Gibson A, Falgari G, Brennan K, Farnie G, Buus R, Marlow R, Novo D, Knight E, Guppy N, Kolarevic D, Susnjar S, Milijic NM, Naidoo K, Gazinska P, Roxanis I, Pancholi S, Martin LA, Holgersen EM, Cheang MCU, Noor F, Postel-Vinay S, Quinn G, McDade S, Krasny L, Huang P, Daley F, Wallberg F, Choudhary JS, Haider S, Tutt AN, Natrajan R. Peck B, et al. Among authors: buus r. Cancer Res. 2021 Feb 15;81(4):847-859. doi: 10.1158/0008-5472.CAN-20-1822. Epub 2021 Jan 28. Cancer Res. 2021. PMID: 33509944 Free PMC article.
61 results